Latest German inventions Stories
FRAZER, Pa., July 21, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S.
MORRISTOWN, N.J., July 20, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg, a generic equivalent of Opana ERÂ®.
Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models.
SYDNEY and BEDMINSTER, N.J., July 18, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA).
BEVERLY HILLS, Calif., July 5, 2011 /PRNewswire/ -- Dr.
READING, England and BEDMINSTER, N.J., June 30, 2011 /PRNewswire/ -- Archimedes Pharma Ltd., and its subsidiary, Archimedes Pharma U.S. Inc., today announced that the U.S.
More comprehensive statistical analysis shows MoxDuo IR, at equi-analgesic doses to either Morphine or Oxycodone, produced significantly less severe respiratory depression SYDNEY and BEDMINSTER, N.J., June 29, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the release of additional data on its Phase 3 safety study for MoxDuo IR.
LONDON, June 28, 2011 /PRNewswire/ -- Stronger and Effective for Longer Versus Standard Paracetamol Tablets, as Shown in a Dental Pain Study A new non-prescription painkiller is now available in pharmacies across the UK, heralding the first UK painkiller combination of ibuprofen and paracetamol in 'over-the-counter' pain relief.
CHADDS FORD, Pa., June 24, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today issued a voluntary nationwide consumer level recall of EndocetÂ® (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg 100 count bottles, NDC 60951-712-70, Lot # 402415NV and #402426NV.
CHADDS FORD, Pa., June 23, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan.
- A transitional zone between two communities containing the characteristic species of each.